GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

FDA reviewers said in briefing documents that the benefit-risk profile of the drug for the treatment of multiple myeloma “remains unclear.” ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

PDUFA date nears for GSK plc’s Blenrep (belantamab mafodotin), the U.S. FDA’s Oncologic Drugs Advisory Committee will decide July 17 on whether available data justify the return to market of the ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The ...

The Gross Law Firm Reminds GSK plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK Provided by PR Newswire Mar 17, 2025 9:45am.

GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy ...

GSK raised its full-year guidance after reporting a second-quarter adjusted operating profit of £2.2 billion and an above-forecast net profit.

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period ...